🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseLiver biopsy changes on semaglutide — need advice

Liver biopsy changes on semaglutide — need advice

mike.trainer_LA Mon, Jun 23, 2025 at 2:09 AM 14 replies 1,362 viewsPage 1 of 3
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Jun 23, 2025 at 2:09 AM#1

This is the version of the explanation I wish somebody had given me, written down before I forget what confused me. It is about semaglutide, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

The condition it depends on

One condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

The practical version

Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

What I am not sure about

The question I want answered is whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. Numbers rather than impressions, if you have them.

— mike.trainer_LA · corrections welcome and will be edited into this post with credit
33 3Dr.AddMedPHL, newstart_MO, mia_MS2 and 30 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Jun 23, 2025 at 2:39 AM#2
mike.trainer_LA said:
Steady state is the thing most people miss.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Jun 23, 2025 at 3:39 AM
32 2Dr.PulmRoch, maya_sedona, stefan_berlin and 29 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jun 23, 2025 at 3:09 AM#3
mike.trainer_LA said:
Steady state is the thing most people miss.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

That is the short version; the long version is somebody else's post.

31 1julia.endo, JessicaM_2024, TomFromTexas and 28 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Jun 23, 2025 at 3:39 AM#4

Short answer first, then the reasoning. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

30 0TinaHashiRN, robert_kc, dan_philly and 27 others
Reply Quote Save Share Report
MaxMetOK
Member
312
1,123
Dec 2024
Oklahoma
Jun 23, 2025 at 6:22 AM#5
BethLabQueen said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Ask again with the specifics and you will get a better answer than this one.

29 24PurityPaulOR, MaxMetOK, MounjBrad and 26 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register